AVALIAÇÃO NEUROBIOLOGICA DO USO DA RITALINA EM PACIENTES NÃO PORTADORES DE TDHA

The non-therapeutic use of Ritalin, or methylphenidate, among individuals without Attention Deficit Hyperactivity Disorder (ADHD) has increased, especially in academic settings, due to its potential to improve attention and cognitive performance. This study reviews the neurobiological effects of this use in individuals without ADHD. Changes in brain activity, especially in the prefrontal cortex and limbic system, were compared, alterations in dopaminergic neurotransmission were investigated, and differences in neuropsychological performance before and after the use of Ritalin were assessed. The review included articles published between 2011 and 2024 in the PubMed, SciELO, LILACS, and Google Scholar databases, focusing on the neurobiological effects of Ritalin in individuals without ADHD. Results indicate that, despite temporary improvements in concentration and working memory, prolonged use may cause anxiety, tachycardia, changes in appetite, and dependence, as well as reduce the effectiveness of the medication due to tolerance. It is concluded that the risks to physical and mental health outweigh the short-term cognitive benefits. It is essential to raise awareness about the dangers of non-prescribed use of Ritalin and to promote healthy alternatives for cognitive enhancement, as well as to develop evidence-based guidelines to minimize the risks of unsupervised stimulant use.O uso não terapêutico da Ritalina, ou metilfenidato, entre indivíduos sem Transtorno de Déficit de Atenção e Hiperatividade (TDAH) tem aumentado, principalmente em ambientes acadêmicos, devido ao seu potencial para melhorar a atenção e o desempenho cognitivo. Este estudo revisa os efeitos neurobiológicos desse uso em indivíduos sem TDAH. Foram comparadas as alterações na atividade cerebral, especialmente no córtex pré-frontal e sistema límbico, investigadas mudanças na neurotransmissão dopaminérgica e avaliadas as diferenças no desempenho neuropsicológico antes e após o uso da Ritalina.    A revisão incluiu artigos publicados entre 2011 e 2024 nas bases PubMed, SciELO, LILACS e Google Scholar, focando nos efeitos neurobiológicos da Ritalina em indivíduos sem TDAH. Resultados indicam que, apesar de melhorias temporárias na concentração e memória de trabalho, o uso prolongado pode causar ansiedade, taquicardia, alterações no apetite e dependência, além de reduzir a eficácia do medicamento devido à tolerância.    Conclui-se que os riscos à saúde física e mental superam os benefícios cognitivos de curto prazo. É essencial conscientizar sobre os perigos do uso não prescrito da Ritalina e promover alternativas saudáveis para o aprimoramento cognitivo, além de desenvolver diretrizes baseadas em evidências para minimizar os riscos do uso não supervisionado de estimulantes

A epidemiologia da cardiomiopatia de Takotsubo no Brasil e os principais fatores de risco da cardiomiopatia de Takotsubo: The epidemiology of Takotsubo cardiomyopathy in Brazil and the main risk factors for takotsubo cardiomyopathy

A Cardiomiopatia de Takotsubo (CTT) é uma disfunção cardíaca reversível, a qual está relacionada, diretamente, ao estresse físico ou emocional. Objetiva-se através dessa pesquisa evidenciar os principais fatores de risco da CT. Trata-se de uma revisão sistemática realizada no motor de busca Biblioteca Virtual em Saúde (BVS) na base de dados das “Ciências em Saúde em Geral” (Scielo, Medline, Lilacs). Percebeu-se que que a CT apresenta uma ocorrência maior em mulheres na fase de pós-menopausa, onde são atingidas pelo estresse emocional, bem como a inserção de marcapasso também pode desencadear a doença. Entretanto, a etiologia da CT ainda é marcada por controvérsias, mas há concordância acerca do surgimento da CT estar relacionado com a abundância de catecolaminas circulantes

Pervasive gaps in Amazonian ecological research

Biodiversity loss is one of the main challenges of our time,1,2 and attempts to address it require a clear un derstanding of how ecological communities respond to environmental change across time and space.3,4 While the increasing availability of global databases on ecological communities has advanced our knowledge of biodiversity sensitivity to environmental changes,5–7 vast areas of the tropics remain understudied.8–11 In the American tropics, Amazonia stands out as the world’s most diverse rainforest and the primary source of Neotropical biodiversity,12 but it remains among the least known forests in America and is often underrepre sented in biodiversity databases.13–15 To worsen this situation, human-induced modifications16,17 may elim inate pieces of the Amazon’s biodiversity puzzle before we can use them to understand how ecological com munities are responding. To increase generalization and applicability of biodiversity knowledge,18,19 it is thus crucial to reduce biases in ecological research, particularly in regions projected to face the most pronounced environmental changes. We integrate ecological community metadata of 7,694 sampling sites for multiple or ganism groups in a machine learning model framework to map the research probability across the Brazilian Amazonia, while identifying the region’s vulnerability to environmental change. 15%–18% of the most ne glected areas in ecological research are expected to experience severe climate or land use changes by 2050. This means that unless we take immediate action, we will not be able to establish their current status, much less monitor how it is changing and what is being lostinfo:eu-repo/semantics/publishedVersio

Diagnóstico diferencial da Síndrome de Takotsubo e infarto agudo do miocárdio: uma revisão sistemática: Differential diagnosis of Takotsubo Syndrome and acute myocardial infarction: a systematic review

A cardiomiopatia de Takotsubo e o infarto agudo do miocárdio compartilham apresentação clínica e risco de morte semelhantes, embora uma das diferenças mais importantes seja a ausência de doença coronariana obstrutiva na cardiomiopatia de Takotsubo. Neste estudo, tem-se como objetivo analisar a literatura disponível avaliando o diagnóstico diferencial entre pacientes com CTT em comparação com pacientes com infarto agudo do miocárdio. Para isso, foi realizada uma revisão sistemática, utilizando-se a Pubmed e a Medline como base de dados. A partir da análise dos estudos e interpretação de suas principais descobertas, concluiu-se que para pacientes com CTT, outras condições e comorbidades, em vez de apenas dislipidemia e/ou outros fatores de risco estabelecidos, sejam responsáveis por um risco de morte comparável ao de IAM. No entanto, as conclusões desse estudo têm várias limitaçõe

RICORS2040 : The need for collaborative research in chronic kidney disease

Chronic kidney disease (CKD) is a silent and poorly known killer. The current concept of CKD is relatively young and uptake by the public, physicians and health authorities is not widespread. Physicians still confuse CKD with chronic kidney insufficiency or failure. For the wider public and health authorities, CKD evokes kidney replacement therapy (KRT). In Spain, the prevalence of KRT is 0.13%. Thus health authorities may consider CKD a non-issue: very few persons eventually need KRT and, for those in whom kidneys fail, the problem is 'solved' by dialysis or kidney transplantation. However, KRT is the tip of the iceberg in the burden of CKD. The main burden of CKD is accelerated ageing and premature death. The cut-off points for kidney function and kidney damage indexes that define CKD also mark an increased risk for all-cause premature death. CKD is the most prevalent risk factor for lethal coronavirus disease 2019 (COVID-19) and the factor that most increases the risk of death in COVID-19, after old age. Men and women undergoing KRT still have an annual mortality that is 10- to 100-fold higher than similar-age peers, and life expectancy is shortened by ~40 years for young persons on dialysis and by 15 years for young persons with a functioning kidney graft. CKD is expected to become the fifth greatest global cause of death by 2040 and the second greatest cause of death in Spain before the end of the century, a time when one in four Spaniards will have CKD. However, by 2022, CKD will become the only top-15 global predicted cause of death that is not supported by a dedicated well-funded Centres for Biomedical Research (CIBER) network structure in Spain. Realizing the underestimation of the CKD burden of disease by health authorities, the Decade of the Kidney initiative for 2020-2030 was launched by the American Association of Kidney Patients and the European Kidney Health Alliance. Leading Spanish kidney researchers grouped in the kidney collaborative research network Red de Investigación Renal have now applied for the Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS) call for collaborative research in Spain with the support of the Spanish Society of Nephrology, Federación Nacional de Asociaciones para la Lucha Contra las Enfermedades del Riñón and ONT: RICORS2040 aims to prevent the dire predictions for the global 2040 burden of CKD from becoming true